Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells

Fig. 2

Expression changes and anti-VEGF/VEGFR drug efficacies associated with FLT1 and KDR methylation changes. Analysis of gene expression of FLT1 (a) and KDR (b) in 13 RCC lines. Evaluation of the effects of bevacizumab, an anti-FLT1 peptide, an anti-KDR antibody, sunitinib, and axitinib on RCC line proliferation was classified according to the hypermethylation status of FLT1 and/or KDR (c). H460 cells and SNU1 cells were used as control cell lines that lacked or high methylation of either gene, respectively . The error bars show standard errors

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us